Print

Kiadis Pharma Signs License Agreement with Hospira, Inc. (HSP) to Commercialize ATIR(TM) in Europe and Asia  
1/4/2011 9:05:54 AM

(BUSINESS WIRE)--Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma’s ATIR™. ATIR™ is a personalized hematology product designed for blood cancer patients in need of allogeneic bone marrow transplantation who cannot locate a matched donor. The product will enable a mismatched family member to act as donor and is being developed to reduce transplant related mortality caused by infections and graft-versus-host disease.
//-->